Neuroleptic malignant syndrome in the elderly: Diagnostic criteria, incidence, risk factors, pathophysiology, and treatment

Clinical Geriatrics

Volumn 14, Issue 5, 2006, Pages 39-46

  Hall, Ryan C W ^a   Hall, Richard C W ^b   Chapman, Marcia ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANESTHETIC AGENT; ANTIEMETIC AGENT; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DANTROLENE; DIAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; DROPERIDOL; GLUCOCORTICOID; HALOPERIDOL; IRON; LEVODOPA; METHYLPREDNISOLONE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; NITROPRUSSIDE SODIUM; PHENOTHIAZINE; THIOXANTHENE DERIVATIVE; VERAPAMIL;

ACUTE KIDNEY FAILURE; ACUTE PSYCHOSIS; ARTICLE; ASPIRATION PNEUMONIA; DELIRIUM; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; DISEASE PREDISPOSITION; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG WITHDRAWAL; ELDERLY CARE; ELECTROCONVULSIVE THERAPY; HEART ARRHYTHMIA; HUMAN; HYPERKALEMIA; HYPERTHERMIA; HYPOTENSION; INCIDENCE; IRON BLOOD LEVEL; LABORATORY DIAGNOSIS; LIVER TOXICITY; LUNG EMBOLISM; MORTALITY; MUSCLE RIGIDITY; MYOCARDIAL DISEASE; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; PATHOPHYSIOLOGY; PULSATILE DRUG RELEASE; RESPIRATORY FAILURE; RESTLESSNESS; RISK FACTOR; SEPSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33745463755     PISSN: 10951598     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Nicholson D, Chiu W. Neuroleptic malignant syndrome. Geriatrics 2004;59(8):36,38-40.
2. Tsai HC, Kuo PH, Yang PC. Fever, consciousness disturbance, and muscle rigidity in a 68-year-old man with depressive disorder. Chest 2003;124(4):1598-1601.
3. Pope HG Jr, Keck PE Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986;143(10):1227-1233.
4. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142(10):1137-45.
5. Medication-induced movement disorders: Neuroleptic malignant syndrome. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington D.C.: American Psychiatric Association; 2000;795-798.
6. Adityanjee, Singh S, Singh G, Ong S. Spectrum concept of neuroleptic malignant syndrome. Br J Psychiatry 1988;153:107-11.
7. Hall RC, Appleby B, Hall RC. Atypical neuroleptic malignant syndrome presenting as fever of unknown origin in the elderly. South Med J 2005;98(1):114-117.
8. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000;85(1):129-135.
9. Chandran GJ, Mikler JR, Keegan DL. Neuroleptic malignant syndrome: case report and discussion. CMAJ 2003;169(5):439-442.
10. Caroff SN, Rosenberg H, Mann SC, et al. Neuroleptic malignant syndrome in the critical care unit. Crit Care Med 2002;30(11):2609; author reply 2609-2610.
11. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993; 77(1): 185-202.
12. Keck PE Jr, Pope HG Jr, McElroy SL. Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry 1991;148(7):880-882.
13. Stubner S, Rustenbeck E, Grohmann R, et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 2004;37(suppl 1):S54-S64.
14. Takubo H, Harada T, Hashimoto T, et al. A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. Parkinsonism Relat Disord 2003;9(suppl 1):S31-S41.
15. Keck PE Jr, Pope HG Jr, Cohen B, et al. Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry 1989;46(10):914-918.
16. Keck PE Jr, Caroff SN, McElroy SL. Neuroleptic malignant syndrome and malignant hyperthermia: End of a controversy? J Neuropsychiatry Clin Neurosci 1995;7(2):135-144.
17. Berardi D, Amore M, Keck PE Jr, et al. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: A case-control study. Biol Psychiatry 1998;44(8):748-754.
18. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999;156(2): 169-180.
19. Harada T, Mitsuoka K, Kumagai R, et al. Clinical features of malignant syndrome in Parkinson's disease and related neurological disorders. Parkinsonism Relat Disord 2003;9(suppl 1):S15-S23.
20. Adityanjee, Sajatovic M, Munshi KR. Neuropsychiatric sequelae of neuroleptic malignant syndrome. Clin Neuropharmacol 2005;28(4):197-204.
21. Desai A. Use of psychopharmacologic agents in the elderly. Clin Geriatr Med 2003;19(4):697-719.
22. Iwuagwu C, Riley D, Bonoma R. Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a catechol-o-methyl transferase inhibitor. Am J Med 2000;108(6):517-518.
23. Lev R, Clark RF. Neuroleptic malignant syndrome presenting without fever: Case report and review of the literature. J Emerg Med 1994;12(1):49-55.
24. Huang TL, Ree SC, Huang YC, et al. Catatonic features: Differential diagnosis and treatments at an emergency unit. Psychiatry Clin Neurosci 1999;53(1):63-66.
25. Lee J. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry 1998;44(6):499-507.
26. Rosebush PI, Mazurek MF. Serum iron and neuroleptic malignant syndrome. Lancet 1991;338(8760):149-151.
27. Gurrera RJ. Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia? Clin Neuropharmacol 2002; 25(4):183-193.
28. Gurrera RJ, Chang SS. Thermoregulatory dysfunction in neuroleptic malignant syndrome. Biol Psychiatry 1996;39:207-212.
29. Ram A, Cao Q, Keck PE Jr, et al. Structural change in dopamine D2 receptor gene in a patient with neuroleptic malignant syndrome. Am J Med Genet 1995;60(3):228-30.
30. Tollefson GD, Garvey MJ. The neuroleptic syndrome and central dopamine metabolites. J Clin Psychopharmacol 1984;4(3):150-153.
31. Ansseau M, Reynolds CF 3rd, Kupfer DJ, et al. Central dopaminergic and noradrenergic receptor blockade in a patient with neuroleptic malignant syndrome. J Clin Psychiatry 1986;47(6): 320-321.
32. Nishijima K, Ishiguro T. Clinical course and CSF monoamine metabolism in neuroleptic malignant syndrome - a study of nine typical cases and five mild cases. Seishin Shinkeigaku Zasshi 1989;91(6):429-56.
33. Ohkoshi N, Satoh D, Nishi M, Shoji S. Neuroleptic malignant-like syndrome due to donepezil and maprotiline. Neurology 2003;60(6):1050-1051.
34. Serrano-Duenas M. Neuroleptic malignant syndrome-like, or - dopaminergic malignant syndrome - due to levodopa therapy withdrawal. Clinical features in 11 patients. Parkinsonism Relat Disord 2003;9(3):175-178.
35. Ueda M, Hamamoto M, Nagayama H, et al. Biochemical alterations during medication withdrawal in Parkinson's disease with and without neuroleptic malignant-like syndrome. J Neurol Neurosurg Psychiatry 2001;71(1):111-113.
36. Ueda M, Hamamoto M, Nagayama H, et al. Susceptibility to neuroleptic malignant syndrome in Parkinson's disease. Neurology 1999;52(4):777-781.
37. Rosebush PI, Stewart TD, Gelenberg AJ. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry 1989;50(8):295-298. [Erratum in: J Clin Psychiatry 1989;50(12):472.]
38. Sato Y, Asoh T, Metoki N, Satoh K. Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74(5): 574-576.
39. Rosenberg MR, Green M. Neuroleptic malignant syndrome: Review of response to therapy. Arch Intern Med 1989;149(9): 1927-1931.
40. Ihara M, Kohara N, Urano F, et al. Neuroleptic malignant syndrome with prolonged catatonia in a dopa-responsive dystonia patient. Neurology 2002;59(7): 1102-1104.